Health
Decade-Long Study by Fortis Memorial Research Institute (FMRI) Gurugram Reveals Breakthrough in Treating Children with Sickle Cell Disease via Stem Cell Transplant
GURUGRAM, India, November 06, 2025--Fortis Memorial Research Institute, Gurugram, reveals success in curing children with Sickle Cell Disease through Bone Marrow transplantation.
About this update from Fortis Healthcare Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8d6aca31ff16ae34f7be53d5c5653843"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Gta1qjCVja8YekNnxA_sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8d6aca31ff16ae34f7be53d5c5653843","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Srxc2fRq_2uRdPoZwqvSlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8d6aca31ff16ae34f7be53d5c5653843","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Achieves outcomes on par with the world’s best centres, delivering advanced, life-saving care at a fraction of global costs","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"GURUGRAM, India, November 06, 2025--(BUSINESS WIRE)--In a landmark advancement for Indian healthcare, doctors at FMRI, Gurugram, have reported exceptional success in curing children suffering from Sickle Cell Disease (SCD) through Bone Marrow (stem cell) transplantation, a development that places India among the leading nations in advanced paediatric transplant outcomes.","length":373,"tagName":"p"},{"type":"text","content":"The decade-long study, published in the international journal Haemoglobin, analyzed 100 paediatric cases treated between 2015 and 2024. The results demonstrated an overall survival rate of nearly 87%, with 96% success among matched sibling donor transplants and 78% success among half-matched (haploidentical) family donor transplants. These outcomes rank among the best reported globally, marking a significant advancement in the management of Sickle Cell Disease in developing nations.","length":487,"tagName":"p"},{"type":"text","content":"The study highlighted that early diagnosis and timely transplants are critical for long-term survival. Performing the procedure before severe complications such as stroke or organ damage dramatically improves outcomes. Fortis achieved these results using advanced transplant protocols that minimize side effects and reduce the risk of Graft-versus-Host Disease (GVHD), a commonly reported post-transplant complication.","length":418,"tagName":"p"},{"type":"text"...